Baxter International Inc vs Meta Platforms Inc — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Meta Platforms Inc trades at $662.3 (market cap $1.68T). The key difference: Meta Platforms Inc is far larger — about 149.2× Baxter International Inc's market cap, and Baxter International Inc pays the higher dividend (0.92%). Which is the better fit depends on your goals.
| BAX | META | |
|---|---|---|
Market Cap | $11.26B | $1.68T |
Sector | Health | Media |
52-Week High | $29.22 | $790.00 |
52-Week Low | $15.80 | $525.72 |
Enterprise Value | $18.93B | $1.68T |
Dividend Yield | 0.92% | 0.32% |
Volume | — | 24,093,972 |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Meta Platforms (META) trades at $656.73, down 1.86% on the day, amid strong technical and fundamental momentum. The stock maintains a bullish technical signal with key support at $653 and resistance at $663. Recent earnings beats, including Q1 2026 EPS of $10.44 versus $6.70 expected, highlight robust profitability with a 32.84% net margin. The launch of Muse Spark AI and a $21 billion deal with CoreWeave underscore strategic growth initiatives, though legal challenges persist.
Outlook remains positive with a consensus price target of $815.44, implying 24% upside. Strengths include dominant market position, AI innovation, and strong cash flow. Risks involve regulatory lawsuits, high capital expenditure, and competitive pressures. Institutional sentiment is bullish with 79% buy ratings, but investors should monitor litigation outcomes and AI monetization progress.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →